S. Kazemi-bajestani, H. Becher, C. Butts, N. S. Basappa, M. Smylie et al., Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung, J Cachexia Sarcopenia Muscle, vol.10, issue.5, pp.1070-82, 2019.

,

C. Palmela, S. Velho, L. Agostinho, F. Branco, M. Santos et al., Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer, J Gastric Cancer, vol.17, pp.74-87, 2017.

J. Nattenmüller, R. Wochner, T. Muley, M. Steins, S. Hummler et al., Prognostic impact of CT-quantified muscle and fat distribution before and after first-linechemotherapy in lung cancer patients, PloS One, vol.12, p.169136, 2017.

S. Awad, B. H. Tan, H. Cui, A. Bhalla, K. Fearon et al., Marked changes in body composition following neoadjuvant chemotherapy for oesophago-gastric cancer, Clin Nutr, vol.31, pp.74-81, 2012.

M. D. Goncalves, S. Taylor, D. F. Halpenny, E. Schwitzer, S. Gandelman et al., Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer, Clin Radiol, vol.73, p.505, 2018.

Y. Choi, D. Oh, T. Kim, K. Lee, S. Han et al., Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index, PloS One, vol.10, p.139749, 2015.

A. J. Benjamin, M. M. Buschmann, S. Q. Zhang, K. Wroblewski, H. L. Kindler et al., The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer, J Geriatr Oncol, vol.9, 2018.

L. E. Daly, . Bhuachalla-eb-ní, D. G. Power, S. J. Cushen, K. James et al., Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer, J Cachexia Sarcopenia Muscle, vol.9, pp.315-340, 2018.

S. Sasaki, E. Oki, H. Saeki, T. Shimose, S. Sakamoto et al., Skeletal muscle loss during systemic chemotherapy for colorectal cancer indicates treatment response: a pooled analysis of a multicenter clinical trial (KSCC 1605-A), Int J Clin Oncol, vol.24, issue.10, pp.1204-1217, 2019.

S. A. Kurk, P. Peeters, B. Dorresteijn, P. A. De-jong, J. M. Kuijf et al., Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients, J Cachexia Sarcopenia Muscle, vol.9, 2018.

S. Blauwhoff-buskermolen, K. S. Versteeg, M. De-van-der-schueren, N. R. Braver, J. Berkhof et al., Loss of muscle mass during chemo-therapy is predictive for poor survival of patients with metastatic colorectal cancer, J Clin Oncol, vol.34, pp.1339-1383, 2016.

T. Poterucha, B. Burnette, and A. Jatoi, A decline in weight and attrition of muscle in colorectal cancer patients receiving chemotherapy with bevacizumab, Med Oncol, vol.29, pp.1005-1014, 2012.

S. Antoun, M. A. Bayar, V. Dyevre, E. Lanoy, C. Smolenschi et al., No evi-dence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer, BMC Canc, vol.19, p.847, 2019.

J. R. Lieffers, M. Mourtzakis, K. D. Hall, L. J. Mccargar, C. M. Prado et al., A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy de-mands, Am J Clin Nutr, vol.89, pp.1173-1182, 2009.

S. W. Lee, S. G. Yeo, I. Oh, J. H. Yeo, and D. C. Park, Bone mineral density in women treated for various types of gynecological cancer, Asia Pac J Clin Oncol, vol.12, 2016.

D. R. Oostra, M. B. Lustberg, R. E. Reinbolt, X. Pan, R. Wesolowski et al., As-sociation of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer, Mol Cell Endocrinol, vol.402, pp.51-57, 2015.

D. A. Cameron, S. Douglas, J. E. Brown, and R. A. Anderson, Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency?, Breast Canc Res Treat, vol.123, pp.805-819, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00563446

S. K. Hui, A. Khalil, Y. Zhang, K. Coghill, C. Le et al., Longitudinal assessment of bone loss from diagnostic computed tomography scans in gy-necologic cancer patients treated with chemotherapy and radiation, Am J Obstet Gynecol, vol.203, issue.353, pp.1-7, 2010.

P. Hadji, M. Ziller, C. Maskow, U. Albert, and M. Kalder, The influence of chemo-therapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer, Eur J Cancer, vol.45, pp.3205-3217, 2009.

K. Monroy-cisneros, J. Esparza-romero, M. E. Valencia, A. G. Guevara-torres, R. O. Mendez-estrada et al., Antineoplastic treatment effect on bone mineral density in Mexican breast cancer patients, BMC Cancer, vol.16, p.860, 2016.

D. L. Waning and T. A. Guise, Cancer-associated muscle weakness: what's bone got to do with it?, Bonekey Rep, vol.4, p.691, 2015.

L. Cianferotti and M. L. Brandi, Muscleebone interactions: basic and clinical aspects, Endocrine, vol.45, pp.165-77, 2014.

J. N. Regan, T. Trivedi, T. A. Guise, and D. L. Waning, The role of TGFb in bone-muscle crosstalk, Curr Osteoporos Rep, vol.15, pp.18-23, 2017.

L. S. Quinn, B. G. Anderson, L. Strait-bodey, A. M. Stroud, and J. M. Argiles, Oversecretion of interleukin-15 from skeletal muscle reduces adiposity, Am J Physiol Endocrinol Metab, vol.296, 2008.

S. Kandarian, The molecular basis of skeletal muscle atrophy-parallels with osteoporotic signaling, J Musculoskelet Neuronal Interact, vol.8, pp.340-341, 2008.

K. Makki, P. Froguel, and I. Wolowczuk, Adipose tissue in obesity-related inflam-mation and insulin resistance: cells, cytokines, and chemokines, ISRN Inflamm, p.139239, 2013.

J. M. Argiles, F. J. Lopez-soriano, and S. Busquets, Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity, Drug Discov Today, vol.14, pp.208-221, 2009.

J. M. Argiles, J. Lopez-soriano, V. Almendro, S. Busquets, and F. J. Lopez-soriano, Cross-talk between skeletal muscle and adipose tissue: a link with obesity?, Med Res Rev, vol.25, pp.49-65, 2005.

J. S. Damrauer, M. E. Stadler, S. Acharyya, S. Baldwin, M. E. Couch et al., Chemotherapy-induced muscle wasting: association with NF-kB and cancer cachexia, Eur J Transl Myol, vol.28, issue.2, pp.158-66, 2008.

M. A. Ibrahim, G. A. Bakhaat, H. G. Tammam, R. M. Mohamed, and S. A. El-naggar, Cardioprotective effect of green tea extract and vitamin E on Cisplatin-induced cardiotoxicity in mice: toxicological, histological and immunohistochemical studies, Biomed PharmacoTher, vol.113, p.108731, 2019.

L. A. Biondo, H. A. Batatinha, C. O. Souza, A. Teixeira, L. S. Silveira et al., Metformin mitigates fibrosis and glucose intolerance induced by Doxorubicin in subcutaneous adipose tissue, Front Pharmacol, vol.9, p.452, 2018.

T. Ponnapakkam, R. Katikaneni, T. Nichols, G. Tobin, J. Sakon et al., Prevention of chemotherapy-induced osteoporosis by cyclophosphamide with a longacting form of parathyroid hormone, J Endocrinol Invest, vol.34, 2011.

F. Tranquart, P. Dujardin, O. Bouche, C. Marcus, C. Borg et al., Value of contrast-enhanced ultrasound quantification criteria for identifying pa-tients not responding to bevacizumab-based therapy for colorectal liver me-tastases, Ultraschall Med, vol.39, pp.544-58, 2018.

E. A. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-275, 2009.

K. Fearon, F. Strasser, S. D. Anker, I. Bosaeus, E. Bruera et al., Defi-nition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, issue.10, pp.70218-70225, 2011.

C. Prado, J. R. Lieffers, L. J. Mccargar, T. Reiman, M. B. Sawyer et al., Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, vol.9, 2008.

M. Mourtzakis, C. Prado, J. R. Lieffers, T. Reiman, L. J. Mccargar et al., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, vol.33, pp.997-1006, 2008.

W. Shen, M. Punyanitya, Z. Wang, D. Gallagher, M. St-onge et al., Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal crosssectional image, J Appl Physiol, vol.97, 2004.

N. Mitsiopoulos, R. N. Baumgartner, S. B. Heymsfield, W. Lyons, D. Gallagher et al., Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography, J Appl Physiol, vol.85, pp.115-137, 1998.

J. Van-vugt, C. Van-den-braak, R. Schippers, H. Veen, K. M. Levolger et al., Contrast-enhancement influences skeletal muscle density, but not skeletal muscle mass, measurements on computed tomography, Clin Nutr, vol.37, pp.1707-1721, 2018.

K. E. Rollins, H. Javanmard-emamghissi, A. Awwad, I. A. Macdonald, K. Fearon et al., Body composition measurement using computed tomography: does the phase of the scan matter?, Nutrition, vol.41, pp.37-44, 2017.

L. Martin, L. Birdsell, N. Macdonald, T. Reiman, M. T. Clandinin et al., Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index, J Clin Oncol, vol.31, 2013.

H. Gudmundsdottir, B. Jonsdottir, S. Kristinsson, A. Johannesson, D. Goodenough et al., Vertebral bone density in Icelandic women using quantitative computed tomography without an external reference phantom, Osteoporos Int, vol.3, 1993.

S. D. Boden, D. J. Goodenough, C. D. Stockham, E. Jacobs, T. Dina et al., Precise measurement of vertebral bone density using computed tomography without the use of an external reference phantom, J Digit Imag, vol.2, pp.31-39, 1989.

J. K. Brown, W. Timm, G. Bodeen, A. Chason, M. Perry et al., Asynchronously calibrated quantitative bone densitometry, J Clin Densitom, vol.20, pp.216-241, 2017.

L. Wang, Y. Su, Q. Wang, Y. Duanmu, M. Yang et al., Validation of asyn-chronous quantitative bone densitometry of the spine: accuracy, short-term reproducibility, and a comparison with conventional quantitative computed tomography, Sci Rep, vol.7, 2017.

P. J. Pickhardt, G. Bodeen, A. Brett, J. K. Brown, and N. Binkley, Comparison of femoral neck BMD evaluation obtained using Lunar DXA and QCT with asynchronous calibration from CT colonography, J Clin Densitom, vol.18, pp.5-12, 2015.

J. A. Shepherd, J. T. Schousboe, S. B. Broy, K. Engelke, and W. D. Leslie, Executive summary of the 2015 ISCD position development conference on advanced measures from DXA and QCT: fracture prediction beyond BMD, J Clin Densitom, vol.18, pp.274-86, 2015.

A. College and . Radiology, ACR-SPR-SSR practice parameter for the per-formance of quantitative computed tomography (QCT) bone densitometry (amended 2014 resolution 39), 2008.

A. A. Brandes, M. Bartolotti, A. Tosoni, R. Poggi, and E. Franceschi, Practical manage-ment of bevacizumab-related toxicities in glioblastoma, Oncologist, vol.20, pp.166-75, 2015.

L. M. Randall and B. J. Monk, Bevacizumab toxicities and their management in ovarian cancer, Gynecol Oncol, vol.117, pp.497-504, 2010.

, Common Terminology criteria for adverse events (CTCAE) | protocol development | CTEP, p.23, 2019.

M. Caulet, T. Lecomte, O. Bouche, J. Rollin, V. Gouilleux-gruart et al., Bevacizumab pharmacokinetics influence overall and progression-free sur-vival in metastatic colorectal cancer patients, Clin Pharmacokinet, vol.55, pp.1381-94, 2016.

A. J. Macdonald, C. A. Greig, and V. Baracos, The advantages and limitations of cross-sectional body composition analysis, Curr Opin Support Palliat Care, vol.5, 2011.

V. Naganathan and P. Sambrook, Gender differences in volumetric bone density: a study of opposite-sex twins, Osteoporos Int, vol.14, pp.564-573, 2003.

M. Olivan, J. Springer, S. Busquets, A. Tschirner, M. Figueras et al., Theophylline is able to partially revert cachexia in tumour-bearing rats, Nutr Metab, vol.9, p.76, 2012.

A. Barkhudaryan, N. Scherbakov, J. Springer, and W. Doehner, Cardiac muscle wasting in individuals with cancer cachexia, ESC Heart Fail, vol.4, pp.458-67, 2017.

F. Pin, R. Barreto, Y. Kitase, S. Mitra, C. E. Erne et al., Growth of ovarian cancer xenografts causes loss of muscle and bone mass: a new model for the study of cancer cachexia, J Cachexia Sarcopenia Muscle, vol.9, 2018.

A. Bonetto, J. K. Kays, V. A. Parker, R. R. Matthews, R. Barreto et al., Dif-ferential bone loss in mouse models of colon cancer cachexia, Front Physiol, vol.7, p.679, 2016.

J. M. Argiles, B. Stemmler, F. J. Lopez-soriano, and S. Busquets, Inter-tissue communi-cation in cancer cachexia, Nat Rev Endocrinol, vol.15, issue.9, 2018.

R. A. Faulkner, R. G. Mcculloch, S. L. Fyke, D. Coteau, W. E. Mckay et al., Comparison of areal and estimated volumetric bone mineral density values between older men and women, Osteoporos Int, vol.5, pp.271-276, 1995.

R. Ali, V. E. Baracos, M. B. Sawyer, L. Bianchi, S. Roberts et al., Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens, Cancer Med, vol.5, pp.607-623, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01881582